JAK2 and myeloproliferative disorder: Positive JAK2 V617F mutation MPN is associated with longer duration of disease, higher HB level, higher leucocyte count, lower PLT count and higher rate of thrombosis, haemorrhage and fibrosis in comparison to wild-type JAK2 mutation [27].